Cancer Genetics (NASDAQ:CGIX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

CGIX stock opened at $1.09 on Tuesday. Cancer Genetics has a twelve month low of $2.11 and a twelve month high of $17.50. The company’s 50 day moving average is $1.24.

About Cancer Genetics (Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Featured Articles

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.